Nitrazepam Stats & Data

Identification and naming: Nitrazepam is a long-acting nitrobenzodiazepine; common brand name is Mogadon and synonyms include RO 5-3059 and RO 4-5360—use correct naming to avoid confusing it with flunitrazepam or other benzos. Residual impairment: Because the elimination half-life averages 26 hours (range ~15–38 h), next‑day psychomotor impairment and a 'hangover' effect are common, even if you feel subjectively sober. Driving or operating machinery should be avoided until fully recovered. Interindividual variability: Oral bioavailability spans ~53–94%, so two people given the same dose can have very different effects; titrate slowly and avoid stacking doses. Combination risks: Co‑use with opioids, alcohol, barbiturates or GHB/GBL markedly increases the risk of respiratory depression, loss of consciousness and fatal overdose; if any depressants are involved, do not use alone and have naloxone available when opioids are present. General CNS depressant stacking (e.g., Z‑drugs, sedating antihistamines, gabapentinoids) also increases blackout and breathing suppression risk—avoid or use only with strong safeguards. Caffeine and stimulants may mask sedation without restoring coordination or reaction time; DrugBank advises limiting caffeine and strictly avoiding alcohol while on nitrazepam. Tolerance/withdrawal: Regular use can produce tolerance within weeks and dependence; abrupt discontinuation can cause severe withdrawal including seizures—medical tapering is essential. Populations: Older adults and those with liver impairment are more prone to prolonged sedation, confusion, and falls—use lower doses with extra monitoring. Legality/access: Nitrazepam is not marketed in the United States (reducing legitimate supply there); in unregulated markets, counterfeit 'benzos' may contain more potent analogues—drug checking and conservative dosing are strongly advised. Therapeutic note: Beyond hypnotic use, nitrazepam has anticonvulsant properties (e.g., myoclonic seizures), but non-medical redosing to chase sedation can rapidly escalate risk due to delayed peaks and long half-life.